Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleLong-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.
Author(s)Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV
Journal, Volume, IssueJournal of Pain and Symptom Management 1997;14(1):7-14
Major outcome(s)tendency to stable weight for 7 months
IndicationAppetite loss/weight loss;HIV/AIDSAbstract
MedicationDelta-9-THC

We studied the effects of long-term (12 months) dronabinol in 94 late- stage acquired immunodeficiency syndrome (AIDS) patients (mean CD4 count of 45/mm3) who previously participated in a 6-week study (placebo versus dronabinol). All patients received dronabinol orally- 2.5 mg twice daily (90%) or 2.5 mg once daily (10%). Appetite was measured using a visual analogue scale for hunger (VASH). Dronabinol was associated with consistent improvement in mean appetite. Patients previously treated with dronabinol continued to show improvement in VASH (percent change from baseline of 6-week trial: 48.6-76.1% at each month), whereas those previously treated with placebo exhibited substantial improvement in mean appetite, particularly during the initial 4 months of treatment (48.5-69.9%). Thereafter, dronabinol was associated with a VASH change at least twice baseline. Patients tended toward stable body weight for at least 7 months. Adverse events were primarily related to known central nervous system effects of dronabinol. These data support long-term, safe use of dronabinol for anorexia associated with weight loss in patients with AIDS.

Route(s)Oral
Dose(s)2.5 mg once or twice daily
Duration (days)365
Participants94 patients with HIV/AIDS
DesignOpen study
Type of publication
Address of author(s)St. John's Hospital, Tulsa, Oklahoma, USA
Full text

[Back to Overview]  [IACM Homepage]


up